Pub Date : 2025-11-10DOI: 10.1001/jamaneurol.2025.4347
Weichuan Dong,Alex Cabulong,Long Vu,Sadeer G Al-Kindi,David F Warner,Nicholas K Schiltz,Hannah L Fein,Gena R Ghearing,Martha Sajatovic,Siran M Koroukian
ImportanceGeographic variation in epilepsy incidence among older adults may reflect contextual risk factors and point to opportunities for targeted prevention. However, privacy constraints and sparse case counts have historically limited small-area analyses.ObjectiveTo map incident epilepsy among older adults at the smallest geography permissible by privacy constraints and identify contextual social and environmental determinants associated with high-incidence areas.Design, Setting, and ParticipantsThis cohort study examined Medicare administrative claims from 2016 to 2019 for all counties in the contiguous United States. A random sample of 4 999 999 Medicare Fee-for-Service beneficiaries 65 years or older with non-Hispanic Black and Hispanic beneficiaries oversampled at rates of 1.50 and 1.75 times their representation in the study population. Beneficiaries with incident epilepsy were identified by claims criteria and codes from the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, in 2019 and had no epilepsy claims during the period 2016 to 2018. Data were analyzed from January to March 2025.ExposuresArea-level social and environmental determinants of health (SEDH), obtained from publicly available sources and linked to beneficiaries' residences.Main Outcomes and MeasuresThe outcome was area-level epilepsy incidence rate in 2019. To comply with data privacy requirements, the Max-P regionalization method was used to aggregate 3108 counties into 692 "MaxCounties," each containing at least 11 incident cases. Incidence rates per 100 000 persons were mapped. Associations between SEDH variables and epilepsy incidence were estimated using random forest and multivariable logistic regression.ResultsAmong 4 817 147 beneficiaries, 20 263 incident epilepsy cases were identified in 2019 (mean [SD] age, 78.7 [7.5] years; 54.6% women). Incidence rates across MaxCounties varied more than 10-fold (range, 141-1476 per 100 000). In random forest models, higher incidence was associated with insufficient sleep, heat index, physical inactivity, uninsured rate, proportion of non-Hispanic Black residents, and obesity prevalence. In multivariable regression, MaxCounties in the highest tertile for insufficient sleep had nearly double the odds of high epilepsy incidence compared to the lowest tertile (odds ratio [OR], 1.99; 95% CI, 1.10-3.60). Lack of household vehicle access was similarly associated with high incidence (OR, 1.93; 95% CI, 1.16-3.25).Conclusions and RelevanceOur findings highlight the spatial heterogeneity of epilepsy burden in the US Medicare population and underscore the importance of contextual SEDH factors, such as sleep, mobility, and infrastructure, in shaping disease patterns. These insights may help guide targeted public health interventions and resource allocation.
{"title":"Incidence and Risk Factors of Epilepsy Among Older Adults in the US Medicare Population.","authors":"Weichuan Dong,Alex Cabulong,Long Vu,Sadeer G Al-Kindi,David F Warner,Nicholas K Schiltz,Hannah L Fein,Gena R Ghearing,Martha Sajatovic,Siran M Koroukian","doi":"10.1001/jamaneurol.2025.4347","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.4347","url":null,"abstract":"ImportanceGeographic variation in epilepsy incidence among older adults may reflect contextual risk factors and point to opportunities for targeted prevention. However, privacy constraints and sparse case counts have historically limited small-area analyses.ObjectiveTo map incident epilepsy among older adults at the smallest geography permissible by privacy constraints and identify contextual social and environmental determinants associated with high-incidence areas.Design, Setting, and ParticipantsThis cohort study examined Medicare administrative claims from 2016 to 2019 for all counties in the contiguous United States. A random sample of 4 999 999 Medicare Fee-for-Service beneficiaries 65 years or older with non-Hispanic Black and Hispanic beneficiaries oversampled at rates of 1.50 and 1.75 times their representation in the study population. Beneficiaries with incident epilepsy were identified by claims criteria and codes from the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, in 2019 and had no epilepsy claims during the period 2016 to 2018. Data were analyzed from January to March 2025.ExposuresArea-level social and environmental determinants of health (SEDH), obtained from publicly available sources and linked to beneficiaries' residences.Main Outcomes and MeasuresThe outcome was area-level epilepsy incidence rate in 2019. To comply with data privacy requirements, the Max-P regionalization method was used to aggregate 3108 counties into 692 \"MaxCounties,\" each containing at least 11 incident cases. Incidence rates per 100 000 persons were mapped. Associations between SEDH variables and epilepsy incidence were estimated using random forest and multivariable logistic regression.ResultsAmong 4 817 147 beneficiaries, 20 263 incident epilepsy cases were identified in 2019 (mean [SD] age, 78.7 [7.5] years; 54.6% women). Incidence rates across MaxCounties varied more than 10-fold (range, 141-1476 per 100 000). In random forest models, higher incidence was associated with insufficient sleep, heat index, physical inactivity, uninsured rate, proportion of non-Hispanic Black residents, and obesity prevalence. In multivariable regression, MaxCounties in the highest tertile for insufficient sleep had nearly double the odds of high epilepsy incidence compared to the lowest tertile (odds ratio [OR], 1.99; 95% CI, 1.10-3.60). Lack of household vehicle access was similarly associated with high incidence (OR, 1.93; 95% CI, 1.16-3.25).Conclusions and RelevanceOur findings highlight the spatial heterogeneity of epilepsy burden in the US Medicare population and underscore the importance of contextual SEDH factors, such as sleep, mobility, and infrastructure, in shaping disease patterns. These insights may help guide targeted public health interventions and resource allocation.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"168 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145477656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-10DOI: 10.1001/jamaneurol.2025.4415
David S Knopman,Deborah Koltai,Daniel Laskowitz,Jacqueline Becker,Leigh Charvet,Juan Wisnivesky,Alex Federman,Adam Silverstein,Yuliya Lokhnygina,Giuseppina Pilloni,Michelle Haddad,Henry Mahncke,Tom Van Vleet,Rong Huang,Wendy Cox,Diana Terry,Jeannie Karwowski,Netia McCray,Jenny J Lin,Grace A McComsey,Upinder Singh,Linda N Geng,Helen Y Chu,Rebecca Reece,James Moy,Zoe Arvanitakis,Sairam Parthasarathy,Thomas F Patterson,Aditi Gupta,Luis Ostrosky-Zeichner,Jeffrey Parsonnet,Elaine T Kiriakopoulos,Tamara G Fong,Janet Mullington,Sarah Jolley,Nirav S Shah,Sarah Shizuko Morimoto,Joyce K Lee-Iannotti,William D S Killgore,Brigid Dwyer,William Stringer,Carmen Isache,Jennifer A Frontera,Jerry A Krishnan,Ashley O'Steen,Melissa James,Barrie L Harper,Kanecia O Zimmerman,
ImportanceTreatment for cognitive dysfunction due to postacute sequelae of long COVID (ie, symptoms of fatigue, malaise, weakness, confusion that persist beyond 12 weeks after an initial COVID infection) remains a significant unmet need.ObjectiveTo test evidence-based rehabilitation strategies for improving cognitive symptoms in persons with long COVID.Design, Setting, and ParticipantsThis was a 5-arm, multicenter, randomized clinical trial of 3 remotely delivered interventions conducted between August 17, 2023, and June 10, 2024. The study took place at 22 trial sites and included the screening of individuals with cognitive long COVID.InterventionsParticipants were randomized to 1 of 5 arms: adaptive computerized cognitive training (BrainHQ [Posit Science]), cognitive-behavioral rehabilitation involving both group and individual counseling sessions (PASC-Cognitive Recovery [PASC-CoRE]) paired with BrainHQ, and transcranial direct current stimulation (tDCS) paired with BrainHQ. Two comparator arms were included as follows: unstructured computer puzzles and games (active comparator) and sham tDCS paired with BrainHQ. The interventions occurred 5 times per week over 10 weeks.Main Outcomes and MeasuresCognitive and behavioral in-person assessments were performed at baseline, midintervention, at the end of intervention, and 3 months after the end of the intervention. The primary outcome measure was the modified Everyday Cognition Scale 2 (ECog2) completed at the end of the intervention compared to the baseline visit based on participant self-report looking back over the prior 7 days.ResultsA total of 378 individuals were screened, from which there were 328 participants (median [IQR] age, 48.0 [37.0-58.0] years; 241 female [73.5%]; race: 15 Asian [4.6%], 47 Black [14.3%], and 235 White [71.6%]; ethnicity: 52 Hispanic [15.9%]). None of the 3 active interventions demonstrated benefits on the modified ECog2 in the intention-to-treat population by the end of the intervention period. The adjusted differences in mean change were 0.0 (95% CI, -0.2 to 0.2) for BrainHQ vs active comparator, 0.1 (95% CI, -0.1 to 0.3) for PASC-CoRE + BrainHQ vs active comparator, 0.0 (95% CI, -0.2 to 0.2) for tDCS-active + BrainHQ vs tDCS-sham + BrainHQ, and 0.1 (95% CI, -0.1 to 0.3) for PASC-CoRE + BrainHQ vs BrainHQ alone. Secondary participant-reported outcomes and neuropsychological tests showed no differential benefits for any treatment arm. All 5 arms demonstrated some improvements over time on the modified ECog2 and on secondary outcomes. There were no serious adverse events attributable to the interventions.Conclusions and RelevanceThis phase 2 randomized clinical trial failed to demonstrate differential benefits for online cognitive training, a structured cognitive rehabilitation program, and tDCS for cognitive long COVID.Trial RegistrationClinicalTrials.gov Identifier: NCT05965739.
{"title":"Evaluation of Interventions for Cognitive Symptoms in Long COVID: A Randomized Clinical Trial.","authors":"David S Knopman,Deborah Koltai,Daniel Laskowitz,Jacqueline Becker,Leigh Charvet,Juan Wisnivesky,Alex Federman,Adam Silverstein,Yuliya Lokhnygina,Giuseppina Pilloni,Michelle Haddad,Henry Mahncke,Tom Van Vleet,Rong Huang,Wendy Cox,Diana Terry,Jeannie Karwowski,Netia McCray,Jenny J Lin,Grace A McComsey,Upinder Singh,Linda N Geng,Helen Y Chu,Rebecca Reece,James Moy,Zoe Arvanitakis,Sairam Parthasarathy,Thomas F Patterson,Aditi Gupta,Luis Ostrosky-Zeichner,Jeffrey Parsonnet,Elaine T Kiriakopoulos,Tamara G Fong,Janet Mullington,Sarah Jolley,Nirav S Shah,Sarah Shizuko Morimoto,Joyce K Lee-Iannotti,William D S Killgore,Brigid Dwyer,William Stringer,Carmen Isache,Jennifer A Frontera,Jerry A Krishnan,Ashley O'Steen,Melissa James,Barrie L Harper,Kanecia O Zimmerman, ","doi":"10.1001/jamaneurol.2025.4415","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.4415","url":null,"abstract":"ImportanceTreatment for cognitive dysfunction due to postacute sequelae of long COVID (ie, symptoms of fatigue, malaise, weakness, confusion that persist beyond 12 weeks after an initial COVID infection) remains a significant unmet need.ObjectiveTo test evidence-based rehabilitation strategies for improving cognitive symptoms in persons with long COVID.Design, Setting, and ParticipantsThis was a 5-arm, multicenter, randomized clinical trial of 3 remotely delivered interventions conducted between August 17, 2023, and June 10, 2024. The study took place at 22 trial sites and included the screening of individuals with cognitive long COVID.InterventionsParticipants were randomized to 1 of 5 arms: adaptive computerized cognitive training (BrainHQ [Posit Science]), cognitive-behavioral rehabilitation involving both group and individual counseling sessions (PASC-Cognitive Recovery [PASC-CoRE]) paired with BrainHQ, and transcranial direct current stimulation (tDCS) paired with BrainHQ. Two comparator arms were included as follows: unstructured computer puzzles and games (active comparator) and sham tDCS paired with BrainHQ. The interventions occurred 5 times per week over 10 weeks.Main Outcomes and MeasuresCognitive and behavioral in-person assessments were performed at baseline, midintervention, at the end of intervention, and 3 months after the end of the intervention. The primary outcome measure was the modified Everyday Cognition Scale 2 (ECog2) completed at the end of the intervention compared to the baseline visit based on participant self-report looking back over the prior 7 days.ResultsA total of 378 individuals were screened, from which there were 328 participants (median [IQR] age, 48.0 [37.0-58.0] years; 241 female [73.5%]; race: 15 Asian [4.6%], 47 Black [14.3%], and 235 White [71.6%]; ethnicity: 52 Hispanic [15.9%]). None of the 3 active interventions demonstrated benefits on the modified ECog2 in the intention-to-treat population by the end of the intervention period. The adjusted differences in mean change were 0.0 (95% CI, -0.2 to 0.2) for BrainHQ vs active comparator, 0.1 (95% CI, -0.1 to 0.3) for PASC-CoRE + BrainHQ vs active comparator, 0.0 (95% CI, -0.2 to 0.2) for tDCS-active + BrainHQ vs tDCS-sham + BrainHQ, and 0.1 (95% CI, -0.1 to 0.3) for PASC-CoRE + BrainHQ vs BrainHQ alone. Secondary participant-reported outcomes and neuropsychological tests showed no differential benefits for any treatment arm. All 5 arms demonstrated some improvements over time on the modified ECog2 and on secondary outcomes. There were no serious adverse events attributable to the interventions.Conclusions and RelevanceThis phase 2 randomized clinical trial failed to demonstrate differential benefits for online cognitive training, a structured cognitive rehabilitation program, and tDCS for cognitive long COVID.Trial RegistrationClinicalTrials.gov Identifier: NCT05965739.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"29 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145477605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-03DOI: 10.1001/jamaneurol.2025.4286
,Hyun Jin Han,Yun Seo Kim,Seoyeon Park,Jae Il Shin,Min Seo Kim,Ju Hyung Moon,Yong Bae Kim,Hazim S Ababneh,Ahmed Abu-Zaid,Demelash Areda,Santhosh Arul,Ahmed Y Azzam,Mainak Bardhan,Mohammad Amin Bayat Tork,Babak Behnam,Gokce Belge Bilgin,Prarthna V Bhardwaj,Soumitra S Bhuyan,Nima Broomand Lomer,Meng Xuan Chen,Suma Sri Chennapragada,Xiaochen Dai,Frances E Dean,Sindhura Deekonda,Xueting Ding,Ojas Prakashbhai Doshi,Abdel Rahman E'mar,Muhammed Elhadi,Jawad Fares,Patrick Fazeli,James L Fisher,Maryam Fotouhi,Ali Gholamrezanezhad,Fidelia Ida,Chidozie Declan Iwu,Mohamed Jalloh,Chinmay T Jani,Rizwan Kalani,Samuel Berchi Kankam,Foad Kazemi,Ariz Keshwani,Atulya Aman Khosla,Stephen S Lim,Riffat Mehboob,Tomislav Mestrovic,Ali H Mokdad,Christopher J L Murray,Gurudatta Naik,Zuhair S Natto,Dang Nguyen,Fred Nugen,Atakan Orscelik,Romil R Parikh,Louise Penberthy,Richard G Pestell,Disha Prabhu,Jagadeesh Puvvula,Shakthi Kumaran Ramasamy,Cameron John Sabet,Austin E Schumacher,Yigit Can Senol,Sunder Sham,Samendra P Sherchan,Gizeaddis Lamesgin Simegn,Jasvinder A Singh,Ranjan Solanki,Bahadar S Srichawla,Jabeen Taiba,Manoj Tanwar,Mike Tuffour Amirikah,Anjul Verma,Ismaeel Yunusa,David X Zheng,Dong Keon Yon,Keun Young Park
ImportancePrimary brain and central nervous system cancer (collectively referred to as CNS cancer) comprises 2% of all human cancers and poses significant health and economic challenges in the United States.ObjectiveTo analyze CNS cancer burden in the US, stratified by time, location (state and division), sex, age group, and Sociodemographic Index (SDI).Design, Setting, and ParticipantsThis cross-sectional study involved a repeated analysis of Global Burden of Disease Study (GBD) 2021 data in 2024. Using data from 183 sources, CNS cancer metrics in the US were estimated across states and years. US CNS cancer metrics across all sexes and age groups were included in the GBD.ExposureCNS cancer diagnosis.Main Outcomes and MeasuresOverall and age-standardized estimates of the incidence, prevalence, mortality, disability-adjusted life-years (DALYs), years of life lost, and years lived with disability per 100 000 population, including 95% uncertainty intervals (UIs), and time trends.ResultsIn 2021, for all age groups and sexes across the US, there were 31 780 incident cases (95% UI, 29971.1 to 32843.9). Age-standardized incidence, DALYs, and mortality rates per 100 000 population were 6.91 (95% UI, 6.58 to 7.12), 134.38 (95% UI, 129.83 to 137.95), and 4.1 (95% UI, 3.87 to 4.22), respectively. Despite no significant change observed in the overall incidence between 1990 and 2021, DALY and mortality rates decreased by 15.77% (95% UI, -17.75% to -13.68%) and 8.41% (95% UI, -11.09% to -6.22%), respectively. Substantial geographic variability was noted. Mississippi, Alabama, Kentucky, and Kansas (West North Central and East South Central divisions) and West Virginia faced persistently high burdens over the past 30 years. Sex differences were evident; disease burden was consistently higher in males compared with females. Age-specific estimates showed a bimodal distribution: the youngest group (<5 years) showed a significant decrease in incidence rate (-34.42% to -11.56%), whereas older age groups (>70 years) experienced increasing trends. DALYs and mortality rates were negatively correlated with SDI (ρ = -0.6860 and ρ = -0.6391; P < .001).Conclusions and RelevanceThese findings provide valuable insights into the CNS cancer burden across the US by age, sex, location, and SDI, enabling better public health status assessments, health care policy restructuring, and resource redistribution for improved care.
{"title":"Burden of Central Nervous System Cancer in the United States, 1990-2021.","authors":" ,Hyun Jin Han,Yun Seo Kim,Seoyeon Park,Jae Il Shin,Min Seo Kim,Ju Hyung Moon,Yong Bae Kim,Hazim S Ababneh,Ahmed Abu-Zaid,Demelash Areda,Santhosh Arul,Ahmed Y Azzam,Mainak Bardhan,Mohammad Amin Bayat Tork,Babak Behnam,Gokce Belge Bilgin,Prarthna V Bhardwaj,Soumitra S Bhuyan,Nima Broomand Lomer,Meng Xuan Chen,Suma Sri Chennapragada,Xiaochen Dai,Frances E Dean,Sindhura Deekonda,Xueting Ding,Ojas Prakashbhai Doshi,Abdel Rahman E'mar,Muhammed Elhadi,Jawad Fares,Patrick Fazeli,James L Fisher,Maryam Fotouhi,Ali Gholamrezanezhad,Fidelia Ida,Chidozie Declan Iwu,Mohamed Jalloh,Chinmay T Jani,Rizwan Kalani,Samuel Berchi Kankam,Foad Kazemi,Ariz Keshwani,Atulya Aman Khosla,Stephen S Lim,Riffat Mehboob,Tomislav Mestrovic,Ali H Mokdad,Christopher J L Murray,Gurudatta Naik,Zuhair S Natto,Dang Nguyen,Fred Nugen,Atakan Orscelik,Romil R Parikh,Louise Penberthy,Richard G Pestell,Disha Prabhu,Jagadeesh Puvvula,Shakthi Kumaran Ramasamy,Cameron John Sabet,Austin E Schumacher,Yigit Can Senol,Sunder Sham,Samendra P Sherchan,Gizeaddis Lamesgin Simegn,Jasvinder A Singh,Ranjan Solanki,Bahadar S Srichawla,Jabeen Taiba,Manoj Tanwar,Mike Tuffour Amirikah,Anjul Verma,Ismaeel Yunusa,David X Zheng,Dong Keon Yon,Keun Young Park","doi":"10.1001/jamaneurol.2025.4286","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.4286","url":null,"abstract":"ImportancePrimary brain and central nervous system cancer (collectively referred to as CNS cancer) comprises 2% of all human cancers and poses significant health and economic challenges in the United States.ObjectiveTo analyze CNS cancer burden in the US, stratified by time, location (state and division), sex, age group, and Sociodemographic Index (SDI).Design, Setting, and ParticipantsThis cross-sectional study involved a repeated analysis of Global Burden of Disease Study (GBD) 2021 data in 2024. Using data from 183 sources, CNS cancer metrics in the US were estimated across states and years. US CNS cancer metrics across all sexes and age groups were included in the GBD.ExposureCNS cancer diagnosis.Main Outcomes and MeasuresOverall and age-standardized estimates of the incidence, prevalence, mortality, disability-adjusted life-years (DALYs), years of life lost, and years lived with disability per 100 000 population, including 95% uncertainty intervals (UIs), and time trends.ResultsIn 2021, for all age groups and sexes across the US, there were 31 780 incident cases (95% UI, 29971.1 to 32843.9). Age-standardized incidence, DALYs, and mortality rates per 100 000 population were 6.91 (95% UI, 6.58 to 7.12), 134.38 (95% UI, 129.83 to 137.95), and 4.1 (95% UI, 3.87 to 4.22), respectively. Despite no significant change observed in the overall incidence between 1990 and 2021, DALY and mortality rates decreased by 15.77% (95% UI, -17.75% to -13.68%) and 8.41% (95% UI, -11.09% to -6.22%), respectively. Substantial geographic variability was noted. Mississippi, Alabama, Kentucky, and Kansas (West North Central and East South Central divisions) and West Virginia faced persistently high burdens over the past 30 years. Sex differences were evident; disease burden was consistently higher in males compared with females. Age-specific estimates showed a bimodal distribution: the youngest group (<5 years) showed a significant decrease in incidence rate (-34.42% to -11.56%), whereas older age groups (>70 years) experienced increasing trends. DALYs and mortality rates were negatively correlated with SDI (ρ = -0.6860 and ρ = -0.6391; P < .001).Conclusions and RelevanceThese findings provide valuable insights into the CNS cancer burden across the US by age, sex, location, and SDI, enabling better public health status assessments, health care policy restructuring, and resource redistribution for improved care.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"69 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145433983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-03DOI: 10.1001/jamaneurol.2025.4240
Sairah Bashir
This essay discusses the role of color psychology in hospital environments and how, by leveraging understanding of how color impacts emotional and psychological states, health care institutions can create spaces that not only treat the body but also support the mind and brain.
{"title":"Butter Yellow—A Soft Hue With Neurological Implications","authors":"Sairah Bashir","doi":"10.1001/jamaneurol.2025.4240","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.4240","url":null,"abstract":"This essay discusses the role of color psychology in hospital environments and how, by leveraging understanding of how color impacts emotional and psychological states, health care institutions can create spaces that not only treat the body but also support the mind and brain.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"156 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145428278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-03DOI: 10.1001/jamaneurol.2025.4224
Sara Hassani, Tonya Roberson, Nicole Rosendale, Lesli E. Skolarus
This essay advocates for community-engaged research as a means to help overcome the delay in disseminating research findings among the general population.
这篇文章提倡社区参与的研究作为一种手段，以帮助克服传播研究成果在普通人群中的延迟。
{"title":"Community-Engaged Research—A Path to More Representative, Efficient, and Impactful Research in Neurology","authors":"Sara Hassani, Tonya Roberson, Nicole Rosendale, Lesli E. Skolarus","doi":"10.1001/jamaneurol.2025.4224","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.4224","url":null,"abstract":"This essay advocates for community-engaged research as a means to help overcome the delay in disseminating research findings among the general population.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"18 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145428290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-03DOI: 10.1001/jamaneurol.2025.4192
Monica Mureb,Shaye Busse,John V Wainwright
{"title":"Intramedullary Hemorrhage Causing Quadriplegia in the Setting of a Type B Aortic Dissection.","authors":"Monica Mureb,Shaye Busse,John V Wainwright","doi":"10.1001/jamaneurol.2025.4192","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.4192","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"128 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145433942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-03DOI: 10.1001/jamaneurol.2025.4232
Kimberly J. Waddell, S. Ryan Greysen, Mitesh S. Patel, Madison S. Smith, Abby Yuen Tsz Lau, Sharon X. Xie, Stephanie Wood, James F. Morley
This nonrandomized clinical trial tests the efficacy of a remote, automated gamification intervention for increasing daily steps in people with Parkinson disease.
这项非随机临床试验测试了远程、自动游戏化干预对帕金森病患者增加每日步数的效果。
{"title":"Remote, Automated Gamification and Community-Based Physical Activity in Parkinson Disease","authors":"Kimberly J. Waddell, S. Ryan Greysen, Mitesh S. Patel, Madison S. Smith, Abby Yuen Tsz Lau, Sharon X. Xie, Stephanie Wood, James F. Morley","doi":"10.1001/jamaneurol.2025.4232","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.4232","url":null,"abstract":"This nonrandomized clinical trial tests the efficacy of a remote, automated gamification intervention for increasing daily steps in people with Parkinson disease.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"25 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145428272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1001/jamaneurol.2025.2562
Mark A Pacult
{"title":"It Ain't About You, Kid.","authors":"Mark A Pacult","doi":"10.1001/jamaneurol.2025.2562","DOIUrl":"10.1001/jamaneurol.2025.2562","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":" ","pages":"1087-1088"},"PeriodicalIF":21.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：